SI3749308T1 - Zdravljenje bolnikov s klasično Fabryjevo boleznijo z migalastatom - Google Patents

Zdravljenje bolnikov s klasično Fabryjevo boleznijo z migalastatom

Info

Publication number
SI3749308T1
SI3749308T1 SI201930691T SI201930691T SI3749308T1 SI 3749308 T1 SI3749308 T1 SI 3749308T1 SI 201930691 T SI201930691 T SI 201930691T SI 201930691 T SI201930691 T SI 201930691T SI 3749308 T1 SI3749308 T1 SI 3749308T1
Authority
SI
Slovenia
Prior art keywords
migalastat
patients
treatment
fabry disease
classic fabry
Prior art date
Application number
SI201930691T
Other languages
English (en)
Slovenian (sl)
Inventor
Jay Barth
Elfrida Benjamin
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65494622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3749308(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of SI3749308T1 publication Critical patent/SI3749308T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201930691T 2018-02-06 2019-02-06 Zdravljenje bolnikov s klasično Fabryjevo boleznijo z migalastatom SI3749308T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862626992P 2018-02-06 2018-02-06
PCT/US2019/016853 WO2019157056A1 (en) 2018-02-06 2019-02-06 Treatment of patients with classic fabry disease
EP19706182.3A EP3749308B1 (en) 2018-02-06 2019-02-06 Treatment of patients with classic fabry disease with migalastat

Publications (1)

Publication Number Publication Date
SI3749308T1 true SI3749308T1 (sl) 2024-03-29

Family

ID=65494622

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201930691T SI3749308T1 (sl) 2018-02-06 2019-02-06 Zdravljenje bolnikov s klasično Fabryjevo boleznijo z migalastatom

Country Status (20)

Country Link
US (1) US20210038579A1 (https=)
EP (2) EP4316589A3 (https=)
JP (2) JP2021512896A (https=)
KR (1) KR20200128675A (https=)
CN (1) CN112203657A (https=)
AR (1) AR114392A1 (https=)
AU (2) AU2019217603A1 (https=)
DK (1) DK3749308T3 (https=)
ES (1) ES2969263T3 (https=)
FI (1) FI3749308T3 (https=)
HR (1) HRP20240025T1 (https=)
HU (1) HUE064761T2 (https=)
LT (1) LT3749308T (https=)
PL (1) PL3749308T3 (https=)
PT (1) PT3749308T (https=)
RS (1) RS65103B1 (https=)
SI (1) SI3749308T1 (https=)
SM (1) SMT202400027T1 (https=)
TW (2) TWI869336B (https=)
WO (1) WO2019157056A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CA3224537C (en) 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4282472A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
EP3851105B1 (en) 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ES2573498T3 (es) * 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
AU2008232614A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
KR102004114B1 (ko) * 2016-03-22 2019-07-26 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 g9331a 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
AR109103A1 (es) 2016-07-19 2018-10-31 Amicus Therapeutics Inc Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
WO2019017938A1 (en) * 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES

Also Published As

Publication number Publication date
SMT202400027T1 (it) 2024-03-13
JP2021512896A (ja) 2021-05-20
HUE064761T2 (hu) 2024-04-28
CN112203657A (zh) 2021-01-08
ES2969263T3 (es) 2024-05-17
WO2019157056A8 (en) 2020-12-03
DK3749308T3 (da) 2024-01-22
RS65103B1 (sr) 2024-02-29
EP4316589A3 (en) 2024-04-24
WO2019157056A1 (en) 2019-08-15
AU2019217603A1 (en) 2020-09-24
EP3749308A1 (en) 2020-12-16
JP2024026080A (ja) 2024-02-28
CA3090499A1 (en) 2019-08-15
KR20200128675A (ko) 2020-11-16
HRP20240025T1 (hr) 2024-03-29
FI3749308T3 (fi) 2024-01-18
US20210038579A1 (en) 2021-02-11
TWI869336B (zh) 2025-01-11
EP3749308B1 (en) 2023-10-25
AR114392A1 (es) 2020-09-02
LT3749308T (lt) 2024-02-12
EP4316589A2 (en) 2024-02-07
PT3749308T (pt) 2024-01-25
TW201944998A (zh) 2019-12-01
AU2025200074A1 (en) 2025-01-30
PL3749308T3 (pl) 2024-03-25
TW202537622A (zh) 2025-10-01

Similar Documents

Publication Publication Date Title
IL276383B1 (en) Treatment of ophthalmological diseases
PL3749308T3 (pl) Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem
IL264301A (en) Treatment of Fabry disease in ert-naive and ert-experienced patients
SG11202107325TA (en) Methods and compositions for the treatment of fabry disease
ZA202108219B (en) Combination treatment of arthritic disease
IL269083A (en) Methods for preventing and treating heart disease
IL268357A (en) Photoreceptor cells for the treatment of retinal diseases
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
PL3268029T3 (pl) Leczenie pacjentów z cukrzycą typu 2
SG11202103972SA (en) Neurological disease treatment with zilucoplan
IL253460A0 (en) Lixanitide treatment in pediatric patients with type 2 diabetes
GB201805100D0 (en) Treatment of sarcopenic diseases
SG11202010585WA (en) New treatment of interstitial lung diseases
IL282360A (en) Treatment for neurological diseases
IL254500A0 (en) Treatment of patients with type 2 diabetes
PL3710043T3 (pl) Fgf10 do leczenia chorób serca
IL263837A (en) Treatment of ocular disease
LT3609486T (lt) Sarpogrelatas, skirtas naudoti žinduolių širdies ligų gydymo būdui
GB201811912D0 (en) Treatment of disease
GB201811911D0 (en) Treatment of disease
GB201810974D0 (en) Treatment of disease
GB201909438D0 (en) Treatment of diseases
ZA201904327B (en) Treatment of skin conditions
GB201705435D0 (en) Treatment of ocular disease
SG11202007642RA (en) Treatment of disorders with tasimelteon